Home / Blog
Global Autism Spectrum Disorder Diagnosis And Therapeutics Market Is Valued At 7997.8 Million US$ In 2018
Wednesday, 06 May, 2020
Autism spectrum disorder is a biologically based neurodevelopmental disorder characterized by persistent deficits in social communication and social interaction and restricted, repetitive patterns of behavior, interests and activities. Diagnosing autism spectrum disorder (ASD) can be difficult, since there is no medical test, like a blood test, to diagnose the disorders. Doctors look at the child’s behavior and development to make a diagnosis. Our report studies the market from 2014-2025, examining programs and medications used to the patient with autism.

The global Autism Spectrum Disorder Diagnosis and Therapeutics market is valued at 7997.8 Million US$ in 2018 and will reach 10587.6 Million US$ by the end of 2025, growing at a CAGR of 4.09% during 2019 and 2025. 

Industry concentration is relatively low. The revenue market share of Otsuka is about 6.78% in 2018. The other competitors include AstraZeneca, Pfizer, Eli Lilly and Johnson & Johnson among others.

In terms of type, Autistic Disorder occupied a larger market share, in 2018, Autistic Disorder occupied 35.38% market share in global Autism Spectrum Disorder Diagnosis and Therapeutics market.

Over the past few years, with the increased number of infants and toddlers diagnosed with ASD. The global autism disorder and treatment market has been identified as one of the rapidly growing industries, owing to rising prevalence of autism and Pervasive Developmental Disorder (PDD) and rising awareness about autism among the patient population. Autism disorder and treatment is observed as one of the significantly growing markets in the healthcare sector because of initiatives taken by the government of various nations and expected approvals of various off-label treatment therapies by the Food and Drug Association (FDA). In the coming years, Autism Spectrum Disorder Diagnosis and Therapeutics market is expected to grow steadily.